Weight Loss from Ozempic Is NOT Sustainable After Discontinuation
Weight loss achieved with Ozempic (semaglutide) is not sustainable after stopping the medication—patients regain approximately two-thirds of their lost weight within one year of discontinuation. 1
Evidence of Weight Regain After Discontinuation
The data on weight regain after stopping semaglutide is remarkably consistent across multiple high-quality studies:
In the STEP 1 extension trial, patients who discontinued semaglutide after 68 weeks regained 11.6 percentage points of their lost weight over the subsequent 52 weeks 1. This represents approximately two-thirds of the total weight loss achieved during treatment 2.
In the STEP 4 withdrawal trial, participants who switched from semaglutide to placebo after 20 weeks gained 6.9% of body weight during the 48-week placebo period, while those continuing semaglutide lost an additional 7.9%—a 14.8 percentage point difference 3.
The 2025 American Diabetes Association guidelines explicitly state that sudden discontinuation of semaglutide results in regain of one-half to two-thirds of the weight loss within 1 year 1.
Why Weight Regain Occurs
The biological mechanisms driving weight regain are well-established:
Obesity is a chronic disease requiring ongoing treatment 1. When semaglutide is discontinued, the pharmacologic suppression of appetite, delayed gastric emptying, and metabolic effects cease 4.
Compensatory biological changes prevent maintenance of long-term weight loss after drug withdrawal 5. The body's homeostatic mechanisms work to restore previous weight set points.
Cardiometabolic improvements achieved during treatment (including reductions in blood pressure, cholesterol, and glucose) also revert toward baseline after discontinuation 2.
Clinical Implications for Long-Term Management
Patients should be counseled that antiobesity medications must be used in conjunction with lifestyle changes and may need to be used lifelong 1.
Recommended Approaches:
Continue pharmacotherapy long-term on the lowest effective dose for patients who achieve early weight loss (typically >5% after 3 months) 1.
Use shared decision-making to determine the best long-term approach, which may include continuing medication, intermittent therapy, or stopping with close weight monitoring 1.
For patients who must discontinue, intensify lifestyle interventions including structured dietary programs and increased physical activity to minimize weight regain 1, 3.
Limited Evidence for Weight Maintenance Strategies
While some small studies suggest potential mitigation strategies, the evidence is limited:
One observational study in women with PCOS showed that continuing metformin 2000 mg daily after semaglutide discontinuation resulted in regain of only one-third of lost weight over 2 years 5. However, this was a small study (n=25) in a specific population and requires validation.
Factors potentially supporting weight maintenance include early treatment initiation, non-geriatric age, strength training, and sustained diet modification 6, though these have not been rigorously tested in controlled trials.
Common Pitfalls to Avoid
Do not present semaglutide as a short-term weight loss solution. Patients must understand the chronic nature of obesity treatment before initiating therapy 1.
Avoid treatment inertia. For patients not maintaining weight goals after discontinuation, reevaluate and intensify treatment with additional approaches including restarting medication, adding other agents, or considering metabolic surgery 1.
Monitor weight trajectory closely after discontinuation (e.g., unintentional weight gain >2 kg in a month or ≥7% increase from baseline) 1.
The half-life of semaglutide is approximately 1 week, meaning it remains in circulation for about 5 weeks after the last dose 4—weight regain may not be immediately apparent.